Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.
You may also be interested in...
Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.
Rebates would be prohibited and insurance coverage required without restrictions for insulin products with steep price roll-backs under bill from Reps. Diana DeGette, D-CO, and Tom Reed, R-NY.
Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30.